<DOC>
	<DOCNO>NCT00703820</DOCNO>
	<brief_summary>The purpose study assess feasibility efficacy novel form therapy—haploidentical NK cell transplantation—in patient standard-risk AML . In addition , investigate efficacy clofarabine + cytarabine ( Clo/AraC ) newly diagnose patient AML attempt optimize outcome use MRD-adapted therapy improvement supportive care .</brief_summary>
	<brief_title>Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>The overall objective protocol improve cure rate acute myeloid leukemia ( AML ) . We compare immunologic complete response rate one course therapy patient receive cytarabine + daunorubicin + etoposide ( ADE ) patient receive clofarabine + cytarabine ( Clo/AraC ) Secondary objective include - To estimate event-free survival ( EFS ) standard risk ( SR ) patient receive chemotherapy alone EFS SR patient receive chemotherapy follow natural killer ( NK ) cell transplantation . Exploratory Objectives : - To genotype natural killer ( NK ) cell receptor measure expression diagnosis induction therapy , explore association feature treatment outcome - To assess prognostic value level minimal residual disease peripheral blood day 8 induction I - To validate new marker method minimal residual disease ( MRD ) detection - To identify new prognostic factor apply new technology study patient material - To identify pharmacogenetic , pharmacokinetic pharmacodynamic predictor treatment-related outcome context systemic therapy use protocol - To describe impact antibiotic antifungal prophylaxis invasive bacterial fungal infection , febrile neutropenia , hospitalization , antibiotic resistance . - To determine performance characteristic broad-range , molecular diagnostic method detection bacterial , fungal , viral agent , comparison method currently routine clinical use Treatment base cytogenetic molecular characteristic , morphology , response therapy assess flow cytometry . Risk group define . The general treatment plan consist chemotherapy LR patient , chemotherapy ± NK cell therapy SR patient , chemotherapy + stem cell transplant ( SCT ) HR patient . HR patient suitable stem cell donor decline SCT eligible NK cell therapy . Low-risk ( LR ) criterion ( eligible SCT NK cell therapy ) - Core binding factor ( CBF ) leukemia [ ( 8 ; 21 ) /AML1-ETO inv ( 16 ) /t ( 16 ; 16 ) /CBF-MYH11 , ] MRD &lt; 0.1 % day 22 , regardless genetic feature . - Patients CBF leukemia MRD ≥ 0.1 % day 22 increasing level fusion transcript consider SR thus eligible NK cell therapy . Standard-risk ( SR ) criterion ( eligible NK cell therapy ) - Absence low-risk high-risk feature . - CBF leukemia MRD ≥ 0.1 % day 22 increasing level fusion transcript - FLT3-ITD MRD &lt; 0.1 % day 22 High-risk ( HR ) criterion ( candidate SCT ; eligible NK cell therapy ) Presence one follow feature : - ( 6 ; 9 ) , ( 8 ; 16 ) , ( 16 ; 21 ) , -7 , -5 , 5q- - FAB M0 M6 - FAB M7 without ( 1 ; 22 ) - Treatment-related ( secondary ) AML - RAEB-2 AML arise prior MDS - FLT3-ITD MRD ≥ 0.1 % day 22 - All patient poor response therapy ( must one follow feature ) MRD ≥ 5 % day 22 MRD ≥ 0.1 % Induction II Induction therapy ( 2 course ) All patient receive two course induction therapy include one course either high dose cytarabine , daunorubicin , etoposide ( HD-ADE ) one course clofarabine cytarabine ( Clo/AraC ) , follow one course low dose cytarabine , daunorubicin , etoposide ( LD-ADE ) . Patients randomly assign receive one follow induction regimen . Induction I : HD-ADE Cytarabine : 3 g/m2 IV 3 hour q12 hour x 6 dos ( day 1 , 3 , 5 ) Daunorubicin : 50 mg/m2 ( 1.67 mg/kg patient less 10 kg ) IV 6 hour day 2 , 4 , 6 ( 3 dos ) Etoposide : 100 mg/m2 IV 4 hour day 2-6 ( 5 dos ) Induction I : Clo/AraC Clofarabine : 52 mg/m2 IV 2 hour day 1-5 ( 5 dos ) Cytarabine : 1 gram/m2 IV 2 hour day 1-5 ( 5 dos ; dose start 4 hour start clofarabine ) Induction II : LD-ADE Cytarabine : 100 mg/m2 IV 30 minute q12 hour day 1-8 ( 16 dos ) , Daunorubicin : 50 mg/m2 ( 1.67 mg/kg patient less 10 kg ) IV 6 hour day 2 , 4 , 6 ( 3 dos ) Etoposide : 100 mg/m2 IV 4 hour day 1-5 ( 5 dos ) Induction II patient FLT3-ITD : LD-ADE + Sorafenib Patients FLT3-ITD take Sorafenib , 400 mg/m2 per day , orally two divided dos ( 200 mg/m2/dose BID ) start one day completion Induction II continue 21 day Patients FLT3-ITD experience toxicity relate Sorafenib also receive 21-day course Sorafenib subsequent course chemotherapy . Induction II HR patient : LD-ADE + vorinostat [ NOTE : Collaborating institution may elect opt treatment vorinostat . If site opts , applicable patient site receive standard induction therapy LD-ADE ( without vorinostat ) . ] Patients M7 AML without ( 1 ; 22 ) HR patient without FLT3-ITD treat combination vorinostat LD-ADE . Vorinostat give orally 3 day ( Days -2 , -1 , 0 ) prior initiation Induction II chemotherapy . Special subgroup HR patient MRD &lt; 0.1 % may proceed directly SCT Induction I suitable donor available transplant perform without delay . Consolidation I : Mitoxantrone : 12 mg/m2 ( 0.4 mg/kg patient less 10 kg ) IV 1 hour day 3-5 ( 3 dos ) Cytarabine : 1 g/m2 IV 2 hour every 12 hour day 1-4 ( 8 dos ) Consolidation II : Cytarabine 3 g/m2 IV 3 hour every 12 hour day 1 , 2 , 8 , 9 ( 8 dos ) . Erwinia Asparaginase 25,000 Units/m2 ( 833 Units/kg infant &lt; 1 month age , infant &lt; 3 month age bear significantly prematurely define &lt; 36 week gestation ) IM IV 1 hour , 3 hour 4th 8th dos cytarabine . NK cell therapy Standard risk patient KIR-mismatched family member great 18 year old undergo NK cell transplantation . In addition , HR patient suitable stem cell donor decline SCT eligible NK cell therapy KIR-mismatched family member . Treatment schema Day -7 : Cyclophosphamide 60 mg/kg IV 1 hour . Mesna 15 mg/kg/dose IV Days -6 -2 : Fludarabine 25 mg/m2/day IV 30 minute ( 5 dos ) Days -1 , +1 , +3 , +5 , +7 , +9 : IL-2 1 million units/m2 give subcutaneously Day -1 : Donor pheresis Day 0 : NK cell infusion No steroid , include use hydrocortisone pre-medication , may give patient 3 day prior NK cell infusion first 7 day infusion . CNS therapy Triple intrathecal therapy methotrexate , hydrocortisone , cytarabine ( MHA ) use CNS therapy dos : &lt; 1 year methotrexate 6 mg , hydrocortisone 12 mg , cytarabine 18 mg , 1-2 year methotrexate 8 mg , hydrocortisone 16 mg , cytarabine 24 mg , 2-3 year methotrexate 10 mg , hydrocortisone 20 mg , cytarabine 30 mg , &gt; 3 year methotrexate 12 mg , hydrocortisone 24 mg , cytarabine 36 mg Leucovorin rescue ( 5 mg/m2 per dose ; 5 mg maximum per dose ) give orally intravenously 24 30 hour IT MHA treatment . Patients evidence CNS disease \ [ ( i.e. , leukemic blast cell cerebrospinal fluid ( CSF ) cytospin ] receive 4 total dos intrathecal therapy , give approximately one month interval begin first 4 course chemotherapy.IT therapy give NK cell therapy . Patients overt CNS leukemia ( less equal 5 leukocyte per l CSF presence leukemic blast cell CSF cytospin ) receive weekly intrathecal therapy CSF free blast cell ( minimum number dos , 4 ) . These patient receive 4 additional dos intrathecal therapy ( minimum total number dos , 8 ) approximately 1-month interval ( generally give subsequent course chemotherapy ) .IT therapy give NK cell therapy . Patients &lt; 5 leukocyte per mul CSF presence leukemic blast cell CSF cytospin ( CNS2 ) receive weekly intrathecal therapy CSF free blast cell . These patient receive 4 additional dos intrathecal therapy approximately 1-month interval ( generally give subsequent course chemotherapy ) .IT therapy give NK cell therapy . Patients unable undergo lumbar puncture receive intrathecal therapy prior start induction I treat CNS2 unless overt CNS leukemia ( CNS3 ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Age le equal 21 year time study entry . No prior therapy malignancy except one dose intrathecal therapy use hydroxyurea lowdose cytarabine ( 100200 mg/m2 per day one week less ) hyperleukocytosis . Written inform consent accord institutional guideline Female patient childbearing potential must negative serum pregnancy test within 2 week prior enrollment Male female participant must use effective contraceptive method study minimum 6 month study treatment . Down syndrome Acute Promyelocytic Leukemia ( APL ) Juvenile Myelomonocytic Leukemia ( JMML ) Fanconi anemia ( FA ) Kostmann syndrome Shwachman syndrome Other bone marrow failure syndrome Use concomitant chemotherapy , radiation therapy , immunotherapy specify protocol . Use investigational agent within 30 day anticancer therapy within 2 week study entry exception IT therapy , hydroxyurea , lowdose cytarabine state . The patient must recover acute toxicity previous therapy . Systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Pregnant lactating patient . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>